News
FDA Approves Replimune’s Tudriqev for Anti-PD-1Refractory Advanced Melanoma
Tudriqev is approved for use in combination with nivolumab to treat adults with unresectable advanced cutaneous melanoma after progression on an anti-PD-1-based regimen.


